Cumulative incidence of the primary composite end point, adjusted for competing risks (death of any cause) by treatment group. The end of the follow-up period was defined as 12 months because no further venous thromboembolism events occurred after this time. ASA indicates aspirin; and LMWH, low-molecular-weight heparin.